Treos Bio Limited

Treos Bio Limited: Develops precision peptide cancer immunotherapies using patient HLA target recognition genetics based on proprietary computational data science. Treos’ lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a biomarker-based Phase 1b clinical trial. Treos has completed preclinical development of additional off-the-shelf immunotherapies in ovarian, breast, bladder, gastric, lung cancers, and melanoma. The Company is also developing off-the-shelf immunotherapies personalized to an individual patient’s HLA genotype for several types of solid tumors. Treos has raised $42 million to date.
Sector/Industry:
Biotech Company / Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
COVID-19, Immunotherapy, Oncology
Industry
Biotechnology
Investment Participation
Series B
Listing
Private
Website:
Profiles:
Address:
The Harley Building
79 New Cavendish Street
London, W1W 6XB
United Kingdom

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Christopher Gallen, CEO